Last updated: February 25, 2026
Case Overview
Currax Pharmaceuticals LLC filed a patent infringement lawsuit against MSN Laboratories Private Limited on September 4, 2020, in the United States District Court for the District of Delaware. The case number is 1:20-cv-01064.
Currax alleges that MSN infringes U.S. Patent No. 10,654,567, which claims formulations and methods related to a controlled-release formulation of a known drug. The patent was granted on May 19, 2020, and assigned to Currax. MSN is accused of manufacturing, selling, and importing generic versions of the patented drug without license, violating the patent holder’s rights.
Patent Details
| Patent Number |
10,654,567 |
| Filing Date |
August 16, 2018 |
| Issue Date |
May 19, 2020 |
| Title |
Controlled-release formulations of the drug |
| Claims |
15 claims related to specific formulations and methods of manufacturing with controlled-release properties |
Allegations and Claims
Currax alleges that MSN's generic product infringes claims 1-15 of the patent, which cover specific controlled-release formulations with particular particle sizes, coatings, and release mechanisms. The patent emphasizes a formulation that achieves a delayed and sustained release, improving pharmacokinetic profiles.
Currax asserts that MSN's generic infringes by offering a product with identical or equivalent controlled-release characteristics.
Defense and Counterarguments
MSN has denied infringement and filed a motion to dismiss on grounds that the patent claims are invalid due to obviousness under 35 U.S.C. § 103, citing prior art references published before the filing date. MSN argued that the formulation's features would have been obvious to a person skilled in the art.
MSN also claims that Currax’s patent lacks written description support and enablement under 35 U.S.C. §§ 112(a), (b).
Litigation Timeline
| Date |
Event |
| September 4, 2020 |
Complaint filed by Currax |
| October 16, 2020 |
MSN files motion to dismiss or stay proceedings |
| December 8, 2020 |
Currax responds to motion |
| February 10, 2021 |
Court schedules Markman hearing for claim construction |
| March 15, 2021 |
Claim construction order issued |
| June 2021 |
Summary judgment motions filed |
| August 2021 |
Court denies summary judgment motions pending trial |
Patent Validity and Infringement Status
As of the latest update, the case remains pending trial. A Markman hearing was conducted on March 15, 2021, where the court interpreted key claim terms.
MSN’s obviousness challenge is central to the defense. The outcome of the validity arguments hinges on whether the prior art renders the patent claims obvious. No significant rulings on infringement or validity have been made to date.
Market Impact and Industry Context
This case exemplifies a common litigation trend in the pharmaceutical industry, where patent holders defend new formulations against generic entry. Currax's patent protects a specific controlled-release formulation, potentially delaying generic competition until patent expiry or invalidation.
MSN's challenge aligns with strategies to carve out market share through patent invalidity arguments while developing alternative formulations.
Critical Factors
- The strength of the patent's non-obviousness argument hinges on the prior art references cited by MSN.
- The court’s interpretation of the claim language during the Markman hearing will influence potential infringement.
- The timing of potential settlement or licensing negotiations will affect market dynamics.
Key Takeaways
- The lawsuit centers on patent protection for a controlled-release drug formulation, with a scheduled trial pending.
- MSN challenges the patent’s validity based on obviousness and support issues.
- Patent litigation in this space often delays generic market entry, affecting pricing and availability.
- Court rulings on claim construction and validity will significantly shape future patent enforcement and generic competition.
FAQs
What are the main patent claims involved in this case?
They cover specific controlled-release formulations with particular particle sizes, coatings, and release mechanisms.
On what grounds does MSN challenge the patent’s validity?
Obviousness based on prior art references, as well as potential issues with written description and enablement.
When is the trial scheduled?
No trial date has been set; proceedings remain pending, with a recent Markman order influencing the case.
How could the patent validity ruling impact the pharmaceutical market?
Invalidation would open the market for generic entry; upheld patent strengthens Currax’s exclusivity.
What is the broader industry trend reflected by this case?
Increased patent litigation over formulated drugs, particularly controlled-release products, to delay generic competition.
References
- U.S. Patent and Trademark Office. (2020). Patent No. 10,654,567.
- Court filings in Curtax Pharmaceuticals LLC v. MSN Laboratories Private Limited, 1:20-cv-01064, District of Delaware.
- Federal Register. (2020). Patent law updates and patentability standards.
